Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Provider network agreement for KidneyIntelX™

April 15, 2020
Download  full announcement Agreement with Three Rivers Provider Network, the fastest growing US proprietary provider network KidneyIntelX   risk assessment testing now available to Three Rivers members and clients Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial

Medicare provider number

April 1, 2020
Keyword Company EPIC/TIDM SEDOL/ISIN News     Price Announcements Fundamentals News Article RSS Renalytix AI PLC (RENX) Add to Alerts list    Print         Mail a friend Wednesday 01 April, 2020 Renalytix AI PLC   RNS Number : 3212I Renalytix AI PLC 01 April 2020     Renalytix AI plc

Presentation of KidneyIntelX™ Health Economics Data

March 27, 2020
Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence  in vitro  diagnostics for kidney disease, announces  that further to  RNS Reach 2937H on 24 March 2020,  Boston Healthcare Associates has presented data on  KidneyIntelX™, the Company’s AI-enabled in

Podium Presentation and Publication for Health Economics Data

March 24, 2020
Presentation   titled:  Evaluation of Payer Budget Impact Associated with the Use of Artificial Intelligence in vitro Diagnostic, KidneyIntelX™, to Modify DKD Progression Oral presentation accepted for  Late Breaking session  of the National Kidney Foundation Spring Clinical Meeting Accompanying

RenalytixAI Announces Podium Presentation and Publication on "Evaluation of Payer Budget Impact Associated with the Use of Artificial Intelligence in vitro Diagnostic, KidneyIntelX™, to Modify DKD Progression"

March 24, 2020
Oral presentation accepted for Late Breaking session of the National Kidney Foundation Spring Clinical Meeting Accompanying abstract accepted for publication in American Journal of Kidney Disease   NEW YORK, March 24, 2020 /PRNewswire/ --  Renalytix AI plc (LSE: RENX),  the AIM-traded developer of

Half-year Report

March 3, 2020
Download  full announcement Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence  in vitro  diagnostics for kidney disease, announces its unaudited interim results for the six months ended 31 December 2019, a period of considerable progress in advancing

Investor briefing

February 26, 2020
Renalytix AI plc (LSE: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that it will release its interim results for the six months ended 31 December 2019, on Tuesday 3 March 2020. Investor briefing A briefing open to all investors will take
Displaying 71 - 80 of 152